Aurigene is a wholly-owned independent subsidiary of Dr. Reddy’s Laboratories. We have strong financials, with profitable operations and a fully de-leveraged balance sheet.

prasad

G V Prasad

CEO – Dr Reddy’s

Mr. G V Prasad is the CEO & Co-Chairman of Dr Reddy’s Laboratories Ltd. Prasad is widely credited as the architect of Dr Reddy’s successful global generics strategy. He envisioned new business platforms like the Custom Pharmaceutical Services business and Specialty Pharmaceuticals and is dedicated to building the innovation side of the business. He is also a champion of sustainability thinking. Prasad earned his degree in Chemical Engineering from the Illinois Institute of Technology in Chicago in 1982 and his Masters in Industrial Administration from Purdue University in 1983.

reddy

Satish Reddy

Chairman – Dr Reddy’s

Mr. Satish Reddy is the Chairman at Dr Reddy’s Laboratories Ltd. Satish steers Dr Reddy’s Pharmaceutical Services and Active Ingredients (PSAI) and Global Generics businesses, two of the company’s core revenue generating stream. Satish graduated in Chemical Engineering from Osmania University, India, in 1988 and went on to receive an MS in Medicinal Chemistry from Purdue University, USA in 1990.

 

chakrabo

Saumen Chakraborty

Member

Mr. Saumen Chakraborty is the President, Chief Financial Officer and Global Head of HR at Dr. Reddy’s. He has over 28 years of experience in both strategic and operational aspects of management. In his previous roles he has been associated with CMC, C-DOT, Eicher & Tecumseh. He is a Graduate in Physics from Visva-Bharati University and has a degree in Management from the Indian Institute of Management, Ahmedabad.

 bruce-carter

Bruce Carter

Member

Dr. Bruce LA Carter is an independent member of the board at Dr. Reddy’s for past 7 years.

He started his long and illustrious career in the Biopharma industry at G.D. Searle & Co. In 1986 he joined ZymoGenetics as Vice President of Research and Development and then went on to head the company as Chief Executive Officer from April 1998 to January 2009. During this period ZymoGenetics was acquired by Novo Nordisk A/S where he served as Corporate Executive Vice President and Chief Scientific Officer from April 1994 to October 1999. Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk in 2000. He has also been the part of academia, as a Lecturer/Professor at Trinity College, University of Dublin and University of Washington. Dr. Carter received a B.Sc. with Honors in Botany from the University of Nottingham, England, and a Ph.D. in Microbiology from Queen Elizabeth College, University of London.

Hari Buggana

Member

Mr. Hari Buggana is the Managing Director of InvAscent India – a private equity firm focused on Indian healthcare, pharma and medtech industries. Prior to this, Hari was a consultant with McKinsey & Company. During his stint at McKinsey, Hari primarily worked with life sciences businesses in the US, Europe, and India on a variety of issues ranging from corporate strategy, mergers & acquisitions, product-market strategy, R&D productivity, organizational effectiveness, and operations improvement. Prior to joining McKinsey, Hari worked as a scientist in the Pharmaceutical Products Division of Abbott Laboratories, USA. Hari has a MBA from Kellogg School of Management, Northwestern University and a M.S. in Chemical Engineering from Illinois Institute of Technology, Chicago.

 knowles

Julius Knowles

Member

Mr. Julius (Jay) Knowles is an investor with Partners Innovation Fund, a $100M fund focused on life science investments in companies emergent from Partners Health Care (the parent organization for Mass General Hospital and Brigham and Womens Hospital, two of the leading academic medical institutions in the US). He was most recently CEO of X-BODY Biosciences, an antibody discovery company, acquired in 2015 by Juno Therapeutics, and before that President of Novalar Pharmaceuticals,a specialty pharmaceutical company that brought a drug from idea stage through the clinic and on to the market. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He represents the fund at the boards of Editas, LTI, Quartet, RaNA and Raze, and is on the board of Aurigene as an independent director.